Loading Events

Past Events › Grant

Events Search and Views Navigation

Event Views Navigation

August 2019

ASGCT Career Development Awards

August 1, 2019

Sponsor: American Society for Cell and Gene Therapy
Application Due Date: August 1, 2019
Awards and Eligibility: ASGCT will award a $50,000 Career Development Award to support independent transformative pilot studies in gene and cell therapy by ASGCT members, particularly those ideas that would be challenging to fund with normal funding mechanisms.

Find out more »

September 2019

Cycle 1: NIH R41, R42, R43, R44, U43, U44

September 5, 2019

 

DUE DATE: SEPTEMBER 5, 2019

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

October 2019

Cycle 3: Whitehall Foundation Grants-in-Aids

October 1, 2019

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: October 1, 2019
Application Due Date: February 15, 2020
Award:  Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.

Find out more »

Cycle 3: Whitehall Foundation Research Grants

October 1, 2019

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: October 1, 2019
Application Due Date: February 15, 2020
Award: Research grants normally range from $30,000 to $75,000 per year for up to three years.

Find out more »

Molecular Mechanisms of Blood-Brain Barrier Function and Dysfunction in Alzheimer’s disease and Alzheimer’s related dementias (AD/ADRD) (R01 Clinical Trial Not Allowed)

October 9, 2019

Sponsor: NIH
LOI Due Date: September 9, 2019
Application Deadline: October 9, 2019
Description:The goal of this initiative is to elucidate the mechanistic links between blood brain barrier (BBB) dysfunction, Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD), and how related comorbidities impact the basic molecular mechanisms of BBB health and function.
Award: Application budgets are limited to $499,000 direct costs/year and need to reflect the actual needs of the proposed project.

Find out more »

Cycle 4: Alzheimer’s Drug Discovery Foundation

October 11, 2019

LOI DUE OCTOBER 11, 2019
Drug Discovery Program
The Drug Discovery RFP supports novel drug programs and repurposed/repositioned programs. One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. The average award is up to $5 million based on stage and scope of research. Depending on the availability of funds, in certain cases, well-justified larger budgets may be considered.
Biomarkers Development
This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Awards range between $50,000-$100,000 for epidemiological analyses based on scope of research, and can reach up to $3 million for clinical trials based on stage and scope of research.

Find out more »

Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)

October 28, 2019

Sponsor: NIH Common Fund Program
LOI Due Date: September 28, 2019
Application Deadline: October 28, 2019
Details: The goal of this funding opportunity announcement (FOA) for the Common Fund Program “Illuminating the Druggable Genome” (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.
Award:  Application budgets are limited to $100,000 in direct costs (excluding subcontract F&A) for one year and need to reflect the actual needs of the proposed project.

Find out more »

November 2019

American Fellowships: Summer/Short-Term Research Publication Grants

November 1, 2019

Sponsor: American Association of University Women Educational Foundation
Due Date: November 1, 2019
Award: $6,000 is available for an eight-week grant period.

Find out more »

Cycle 3: Prevention Research in Mid-Life Adults (R01)

November 5, 2019

Sponsor: National Institutes of Health
Due Date: November 5, 2019 by 5 pm local time of applicant
Award: Money, property, or both to carry out an approved project or activity. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The maximum grant period is five years.

Find out more »

NIH Cycles R01 and U01

November 5, 2019
|Recurring Event (See all)

One event on March 5, 2019 at 12:00 am

One event on November 5, 2019 at 12:00 am

NINDS Exploratory Clinical Trials (U01)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
NINDS Efficacy Clinical Trials (U01)
he purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for  investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS) to establish the efficacy (or compare the effectiveness) of treatment interventions. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Promoting Research in Basic Neuroscience (R01)
The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Prevention Research in Mid-Life Adults (R01)
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Pregnancy in Woman with Disabilities (R01)
Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Application budgets are not limited but need to reflect the actual needs of the proposed project.

 

Find out more »

January 2020

Cycle 1: Whitehall Foundation Grants-In-Aid

January 1, 2020

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.

Find out more »

Healthcare Research by Community Physicians

January 1, 2020

Sponsor: Physicans’ Services Incorporated Foundation

Due Date: Applications accepted on a rolling basis

Award: Grants up to $20,000 are available to cover the costs of the data gathering and analysis,
support staff and preparation of reports. Up to an additional $500 will be provided for travel
costs incurred in presenting papers on the results of a community practice study.

 

Find out more »

Cycle 2: NIH R41, R42, R43, R44, U43, U44

January 5, 2020

DUE DATE: JANUARY 5, 2020

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: Whitehall Foundation Research Grants

January 15, 2020

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Research grants normally range from $30,000 to $75,000 per year for up to three years.

Find out more »

February 2020

NIH R01 Cycles

February 5, 2020
|Recurring Event (See all)

One event on June 5, 2020 at 12:00 am

One event on October 5, 2020 at 12:00 am

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional):
The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. Application budgets are not limited but need to reflect the actual needs of the proposed project.

High Throughput Screening (HTS) to Discover Chemical Probes:
Encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities:
Encourages applications from institutions/ organizations addressing preclinical research in model organisms of neurodevelopmental disorders. Budgets for direct costs of up to $499,999 per year may be requested.

Pregnancy in Women with Disabilities:
This FOA issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grants (R01) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional):
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and well-being as individuals age and prevent illness and disability in later years.Application budgets are not limited but need to reflect the actual needs of the proposed project.

Promoting Research in Basic Neuroscience (R01 Clinical Trial Not Allowed):
he goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Find out more »

April 2020

Cycle 3: NIH R41, R42, R43, R44, U43, U44

April 5, 2020

DUE DATE: APRIL 5, 2020

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

May 2020

Child Neurology Shields Grant

May 1, 2020

Sponsor: Child Neurology Foundation
Due Date: May 1, 2020
Award: The Pediatric Epilepsy Research Foundation (PERF) Shields Research Grant supports translational or clinical research by a child neurologist or developmental pediatrician early in his/her academic career. The selected investigator will receive a $100,000 grant of $50,000 per year for two years.

Find out more »

BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3)

May 23, 2020
|Recurring Event (See all)

One event on September 21, 2020 at 12:00 am

Sponsor: National Institutes of Health
LOI Due Dates: May 23, 2020, September 21, 2020
Application Deadlines: June 22, 2020, October 21, 2020
Award: The NIH anticipates providing $10M per year to fund an estimated 5 to 7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $2M per year.The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study).

Find out more »

June 2020

NIH R01 Cycles

June 5, 2020
|Recurring Event (See all)

One event on June 5, 2020 at 12:00 am

One event on October 5, 2020 at 12:00 am

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional):
The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. Application budgets are not limited but need to reflect the actual needs of the proposed project.

High Throughput Screening (HTS) to Discover Chemical Probes:
Encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities:
Encourages applications from institutions/ organizations addressing preclinical research in model organisms of neurodevelopmental disorders. Budgets for direct costs of up to $499,999 per year may be requested.

Pregnancy in Women with Disabilities:
This FOA issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grants (R01) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional):
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and well-being as individuals age and prevent illness and disability in later years.Application budgets are not limited but need to reflect the actual needs of the proposed project.

Promoting Research in Basic Neuroscience (R01 Clinical Trial Not Allowed):
he goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Find out more »

July 2020

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

July 12, 2020
|Recurring Event (See all)

One event on January 10, 2021 at 12:00 am

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Date: July 12, 2020, January 10, 2021
Application Due Date: August 11, 2020, February 9, 2021
Award: Application budgets are not limited but must reflect the actual needs of the proposed project. Applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories.

Find out more »
+ Export Events